[A18-15] Fluticasone furoate/umeclidinium/vilanterol (COPD) – Benefit assessment according to §35a Social Code Book V

Last updated 16.08.2018

Project no.:

Commission awarded on 27.02.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Airways and respiratory system


Adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2 agonist

Result of dossier assessment:

No statistically significant differences between the treatment groups in the relevant subpopulation of the study included; added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2018-08-16 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form